42nd Pharmacovigilance India

42nd Pharmacovigilance India 2026 is a premier drug safety conference organised to bring together pharmaceutical companies, CROs, regulators and pharmacovigilance professionals to discuss the latest developments shaping the future of pharmacovigilance in India. The event will take place on 23 July 2026 at Radisson Hyderabad Hitec City, Hyderabad, India, providing a focused platform for industry leaders to exchange insights, strengthen safety strategies and build partnerships across the pharmacovigilance ecosystem.

The conference will explore how digital transformation is redefining pharmacovigilance through AI-driven signal detection, automation and machine learning. Discussions will examine the evolution from periodic safety reviews to continuous risk intelligence supported by human-AI collaboration. The programme also addresses regulatory evolution, risk management, pharmacovigilance outsourcing, real-world evidence (RWE), real-world data (RWD) and inspection readiness, enabling participants to stay informed about emerging trends and compliance expectations.

Industry experts from organisations including Amgen, Pfizer, Novartis, Roche–Genentech, AstraZeneca, Bristol Myers Squibb, Sanofi, Cipla, Dr. Reddy’s Laboratories, Glenmark, Zydus Group and others are scheduled to contribute to keynote presentations, panel discussions and case-based sessions. Key themes include intelligent drug safety, combination products, AI-powered pharmacovigilance, outsourcing strategies, risk management frameworks, audit readiness and regulatory collaboration for enhanced patient safety.

The conference is designed to provide a discussion-driven environment focused on knowledge exchange, networking and practical strategies for ensuring safer medicines while navigating the rapidly evolving global pharmacovigilance landscape.